#Dapagliflozin in CKD Patients with #Fabry Disease
#VisualAbstract by Elba Medina
https://www.kireports.org/article/S2468-0249(25)00760-0/fulltext
@pednephrol.bsky.social
Pediatric nephrologist in Belo Horizonte, Brazil (Santa Casa de Belo Horizonte and Nefroclinicas). Special interest in CKD, kidney transplant, glomerulopathies, AKI, dialysis, rare diseases and Winnicott's psychoanalysis.
#Dapagliflozin in CKD Patients with #Fabry Disease
#VisualAbstract by Elba Medina
https://www.kireports.org/article/S2468-0249(25)00760-0/fulltext
Β‘Hola #NephSky @rosertorra.bsky.social @ndt-era.bsky.social
@mdabdulqader83.bsky.social @alanepes.bsky.social
SΓndrome de #Alport y trasplante renal :
The schematic diagram compares traditional versus precision medicine approaches to the treatment of FSGS. By categorizing FSGS into subtypes based on non-invasive molecular and genetic profiling, precision medicine enables initiation of disease modifying therapy that targets the injury pathway activated in an individual patient together with non-specific renoprotective drugs. This combined treatment regimen will increase the likelihood of a treatment response and achieve improved kidney health outcomes compared to sequential prescription of renoprotective agents followed by empirical immunosuppressive therapy (IST). Created with BioRender.com
Current and Future Therapeutics for Focal Segmental Glomerular Sclerosis in the Era of Precision Medicine: A Review
bit.ly/4rb5B6P (OPEN ACCESS)
Evaluation of ravulizumab trough levels in pediatric complement-mediated hemolytic uremic syndrome in remission
Ravulizumab drug monitoring has not been explored for mor maintenance therapy in patients w/complement-mediated (atypical) hemolytic uremic syndrome (aHUS). Read this Original Article on ravulizumab trough levels in aHUS in remission.
link.springer.com/article/10.1...
𧬠C3G
APPEAR-C3G or VALIANT?
π Proteinuria vs placebo:
πΉ Iptacopan: 35%
πΉ Pegcetacoplan: 67%
π― Blocking factor B π π«C3
Where would you place your bet today? #nephsky #Medsky @thelancet.com @nejm.org
π¦ join us today on #nephjc
Local environment, socioeconomic status, and health literacy: key modifiers of adherence in pediatric nephrology
Pediatric nephrology patients have high rates of treatment nonadherence, increasing their risk for poor health outcomes. Read this Educational Review of local environment, socioeconomic status, & health literacy: key modifiers of adherence in pediatric nephrology.
link.springer.com/article/10.1...
ICYMI: RUBY-3 demonstrates that targeting BAFF and APRIL with povetacicept can drive proteinuria reduction and immunologic remission in IgAN and pMN. #KidneyWk #nephsky #Nephrology #ClinicalTrials www.docwirenews.com/post/povetac...
23.12.2025 20:03 β π 2 π 1 π¬ 0 π 0#Antimeningococcal #Protection in Patients Receiving Terminal #ComplementInhibitors
#VisualAbstract by Renz Michael Pasilan
https://www.kireports.org/article/S2468-0249(25)00710-7/fulltext
Interesting discussion as well as results on the proposal of a pediatric KDIGO (p-KDIGO) criteria for AKI in children. Worth the read!
25.12.2025 13:50 β π 2 π 1 π¬ 0 π 0SaΓ―di M, BrochΓ©riou I, EstΓ¨ve E, et al. The Exostosin Immunohistochemical Status Differentiates Lupus Membranous Nephropathy Subsets with Different Outcomes. Kidney Int Rep. 2021;6(7):1977-1980.
24.12.2025 14:22 β π 1 π 1 π¬ 0 π 0Ravindran A, Casal Moura M, Fervenza FC, Nasr SH, et al. In Patients with Membranous Lupus Nephritis, Exostosin-Positivity and Exostosin-Negativity Represent Two Different Phenotypes. J Am Soc Nephrol. 2021 Mar;32(3):695-706.
24.12.2025 14:22 β π 1 π 1 π¬ 1 π 0(1/5) Day 2: Although the findings of membranous (RPS class V) lupus nephritis (LN) are not technically scored by the modified NIH activity index system, it is a variant of LN which occurs with significant proteinuria and potential loss of renal function...
#lupus #pathsky #nephsky
IgG3ΞΊ Monoclonal Membranous Nephropathy Associated With Acquired Lecithin Cholesterol Acyltransferase Deficiency
bit.ly/3Le1OFK
New out today:
Antiproteinuric Effect of Sparsentan in Patients with Genetic-Associated FSGS Enrolled in the DUPLEX Trial
Genetic FSGS CAN be treated. journals.lww.com/cjasn/abstra...
Fenofibrate-Induced Osmotic Nephropathy: A Novel Mechanism of Acute Kidney Injury
Case Report by Raymond Lin, Seethalakshmi Viswanathan, and Nikki L. Wong
bit.ly/4mJDWrz
The image has a red background. On the top left corner in a black box is the text, "ESC." In the upper right corner is the "JN" logo. In the center is the white text, "Read papers from the JAMA Network."
π You can read all the JAMA and @jamacardiology.com papers presented today at #ESCCongress 2025.
ja.ma/4lNEdZf
At the 60th ANZSN Congress in Perth, ISN President-Elect @kidneydoc101.bsky.socialβ¬ joins as speaker & moderator, highlighting ISNβs commitment to global perspectives & collaboration to advance kidney health ππ©Ί
www.theisn.org/blog/2025/09... #ANZSN60
@winnicott-trust.bsky.social There are certainly many admirers of Winnicott's works in bsky.social ! Time to @winnicott-trust.bsky.social help spread his ideas!
17.08.2025 16:58 β π 0 π 0 π¬ 0 π 0Now open access in @ndt-era.bsky.social
Anti-nephrin, anti-podocin and anti-Kirrel1 antibodies: Biological challenges and clinical implications
π§ Clinical implementation of anti-slit diaphragm antibody testing = precision dx and tx in podocytopathies
βΆοΈ academic.oup.com/ndt/article/...
#RenalPath: Antibody-mediated acute rejection with glomerulitis: increased intracapillary leukocytes (arrows) in glomerular tuft (Jones silver stain).
bit.ly/2uShEyu (FREE)
JAMA Special Communication: Reducing Barriers to Mental Health Care for Physicians. Overview & Strategic Recommendations. Published online August 14, 2025. Discusses challenges and initiatives.
Eliminating barriers to #mentalhealth care for physicians is essential to prevent untreated conditions and suicides, improve well-being, and maintain high-quality patient care.
ja.ma/4moVdGo
CALL FOR SUBMISSIONS:
Have you encountered a tricky case that could be submitted as a Quiz to help others learn?
Details on the #AJKDBlog: bit.ly/4bQAHdq
All Quizzes are freely available: bit.ly/40nVK19
Finerenone gets the HFpEF nod from FDA - as expected
NephJC coverage of FINEHEARTS www.nephjc.com/news/fineheart
Our editorial on kidney outcomes from FINEARTS: pubmed.ncbi.nlm.nih.gov/39814475/
Gut microbiota are key regulators of systemic health, influencing kidney development, function, & blood pressure regulation. Read this Review of the role of microbiota-derived short-chain fatty acids in kidney physiology & development. Open Access.
link.springer.com/article/10.1...
Hispanics, the fastest growing minority in the USA, suffer from high CKD burden. Read this Original Article on healthcare access barriers for Hispanic pediatric nephrology patients. Part of a KICK (Kidney Initiative in Community Kids) study. Open Access.
link.springer.com/article/10.1...
New PA Endo guideline is also out by experts @anandvaidya17.bsky.social #Cardiosky @hswapnil.medsky.social doi.org/10.1210/clin...
14.07.2025 18:56 β π 22 π 14 π¬ 1 π 0ποΈWorld-renowned complement expert Carla Nester joins Koyal Jain and @kdjhaveri.bsky.social on GN in Ten to talk C3G and all things complement-mediated kidney disease share.transistor.fm/s/67f1e0de
π More C3G insights on the way after this week's SEISMIC summit is-gd.org/seismic-summit
#RenalPath: CNI nephrotoxicity with TMA involving an arteriole (Jones silver stain).
bit.ly/2qeBWhV (FREE)
Using an MRA empiricially or renin-guided therapy in apparent treatment resistant hypertension?
academic.oup.com/ajh/article/...
#WeekendReads from the #EditorsChoice archives
Herpes Zoster Vaccination and Dementia Occurrence
Herpes zoster vaccination eligibility reduced the probability of new dementia diagnoses, suggesting its potential preventive effect.
https://ja.ma/4lagSB6